Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03417401
Other study ID # S61283
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date October 16, 2018
Est. completion date December 10, 2021

Study information

Verified date March 2023
Source Universitaire Ziekenhuizen KU Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase Ib study investigates the safety and efficacy of performing a retinal vein cannulation with recombinant tissue Plasminogen Activator infusion into a retinal vein with the help of an updated dedicated surgical stabiliser for the treatment of central retinal vein occlusion.


Description:

Investigator-initiated, unmasked, single-arm, mono-center, prospective, interventional case series phase Ib trial. In line with the previous phase I trial, this trial will be biphasic; first 3 patients will be included, when the procedure and product prove to be safe and an added value is noted from the intra-operative OCT-angiography, another 3 will be included afterwards (≥21 days between last inclusion of the first group and first inclusion of the second group).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 10, 2021
Est. primary completion date December 10, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged over 18 years - Recent diagnosis (<8 weeks) of CRVO - Recent onset of symptoms (<12 weeks) - Visual acuity < 5/10 in study eye - Visual acuity >1/10 in fellow eye - Central macular thickness >250µm - Signed informed consent prior to inclusion Exclusion Criteria: - Fluorescein allergy - Active neovascularization - Eye disease other than CRVO or Cataract decreasing central vision - History of retinal surgery - High myopia (> -10D) - Contraindication for the use of systemic anticoagulant medication - Extensive macular ischemia noted on fluo-angiography

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.
Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
Drug:
Intravenous Infusion
Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).

Locations

Country Name City State
Belgium Universitaire Ziekenhuizen Leuven Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen KU Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of retinal vein cannulation successful cannulation defined as peroperatively seen washout of blood in the cannulated retinal vein. The success rate is defined as the number of successful cannulations divided by the total number of cannulation attempts. 10 min
Primary number of intervention-related surgical complications These exist of the intra-operative occurence of:
retinal vein tear (visually seen by the surgeon)
uncontrollable vitreous cavity hemorrhage (as seen by the surgeon)
retinal tear in the proximity of the cannulation site (as seen by the surgeon)
intra-/subretinal injection (as seen by the surgeon)
breakage of the needle (as seen by the surgeon)
failure of stabilizer in holding the instrument immobilized in a certain position (as seen by the surgeon)
7 days
Primary duration of infusion The time of infusion measured during surgery with a maximum of 10 minutes 10 minutes
Primary number of intervention-related non-surgical complications The postoperative occurence of:
hemorrhagic cerebrovascular accidents due to rtPA (confirmed by CT-scan and neurological examination after referral to the neurologist)
large hemorrhage elsewhere to be related with the use of rtPA (as confirmed by clinical examination and/or CT-scan/ultrasound after referral to vascular surgeon)
7 days
Secondary change in visual acuity after 6 to 8 weeks best corrected visual acuity tested with ETDRS chart 6-8 weeks
Secondary change in central macular thickness after 6 to 8 weeks measurement of central macular thickness with spectral domain-OCT 6-8 weeks
Secondary intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA - complications of intraocular surgery:
wound leak tested with concentrated fluorescein (Seidel effect present/absent)
endophthalmitis as seen with the slit lamp/ultrasonography
post-operative macular edema objectivated with OCT imaging
vitreous hemorrhage > 2 weeks after intervention as seen at the slit lamp and confirmed with ultrasonography
development of neovascularization as seen at the slit lamp / fluorescein angiogram
7 days
Secondary intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA - complications during cataract surgery:
iris hemorrhage as seen through the surgical microscope (present/absent)
choroidal swelling as seen through the surgical microscope (present/absent)
suprachoroidal hemorrhage as seen through the surgical microscope (present/absent)
capsule tear as seen through the surgical microscope (present/absent)
dropped lens/intraocular lens (IOL). Recombinant tissue Plasminogen Activator (rtPA) as seen through the surgical microscope (occurred/not occurred)
7 days
Secondary intra-/postoperative complications not related to the surgical stabilizer / retinal vein cannulation / rtPA - complications during vitrectomy:
retinal tears as seen through the surgical microscope (occurred/not occurred)
vitreous hemorrhage as seen through the surgical microscope (occurred/not occurred)
choroidal swelling as seen through the surgical microscope (present/absent)
suprachoroidal hemorrhage as seen through the surgical microscope (present/absent)
7 days
Secondary change in retinal flow intraoperatively visualized with OCT-angiography OCT-angiography visualized flow inside the retinal veins with the intraoperative OCT device; if there is flow the blood vessel is imaged in bright white, if there is no flow the blood vessel is not visible with angio-OCT. 1 hour
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT01969708 - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Phase 3
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Completed NCT03981549 - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Phase 1/Phase 2
Completed NCT02274259 - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Phase 4
Completed NCT01360385 - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab N/A
Not yet recruiting NCT00383773 - Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion N/A
Completed NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion N/A
Recruiting NCT04601701 - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Completed NCT01976312 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Phase 3
Completed NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Phase 1/Phase 2
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Active, not recruiting NCT01011374 - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion Phase 1
Completed NCT03223714 - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Phase 3
Recruiting NCT01827722 - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Phase 4
Completed NCT00906685 - Bevacizumab for Central Retinal Vein Occlusion Study Phase 3
Active, not recruiting NCT04793100 - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections N/A
Recruiting NCT02405741 - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A